© Reuters. FILE PHOTO: The phrases “OMICRON SARS-COV-2” are seen mirrored in a drop from a syringe needle on this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration
BEIJING (Reuters) – China’s Suzhou Abogen Biosciences Co stated its COVID-19 vaccine candidate utilizing the messenger RNA (mRNA) expertise and concentrating on the Omicron variant has obtained medical trial approval within the United Arab Emirates.
With Friday’s announcement, Abogen joins Pfizer/BioNTech and Moderna (NASDAQ:) in trialing candidates modified particularly in opposition to Omicron, a extremely transmissible variant with elevated resistance to antibodies elicited by current pictures.
Mainland China has vaccinated over 88% of its 1.4 billion individuals in opposition to COVID with non-mRNA pictures. It has not accepted any international vaccines, though real-world knowledge indicated the 2 most used Chinese merchandise, manufactured by Sinopharm and Sinovac, have decrease effectiveness in opposition to COVID an infection than mRNA pictures from Pfizer/BioNTech and Moderna.
Besides the UAE, Abogen was speaking with regulators in China and different international locations on potential medical trials for the Omicron-specific candidate, it stated in a press release.
An mRNA candidate based mostly on an older coronavirus pressure with out main mutations, which Abogen co-developed with Walvax Biotechnology and a Chinese military-backed analysis establishment, is being examined in a Phase III trial in China, Mexico and Indonesia.
Walvax can also be partnering with Shanghai-based startup RNACure to develop a variants-targeting mRNA vaccine candidate, with design completely different from Abogen’s.
Two Omicron-specific vaccine candidates from Sinopharm and one from Sinovac, containing inactivated or “killed” coronavirus, have been cleared for medical trials in Hong Kong and mainland China.
The UAE regulator has accepted medical trials for a 3rd Omicron-specific candidate from Sinopharm, based mostly on protein, in addition to for the agency’s two inactivated Omicron-specific candidates, Sinopharm subsidiary China National Biotec Group stated on Friday.